Creative Planning purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 3,070 shares of the company’s stock, valued at approximately $258,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Fred Alger Management LLC raised its stake in TransMedics Group by 281.0% during the first quarter. Fred Alger Management LLC now owns 1,143,639 shares of the company’s stock worth $86,608,000 after purchasing an additional 843,434 shares during the period. Summit Partners Public Asset Management LLC raised its position in TransMedics Group by 71.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after purchasing an additional 400,255 shares during the period. Allspring Global Investments Holdings LLC raised its position in TransMedics Group by 36.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,294,430 shares of the company’s stock valued at $108,706,000 after purchasing an additional 346,727 shares during the period. BlackRock Inc. raised its position in TransMedics Group by 16.1% in the third quarter. BlackRock Inc. now owns 2,198,654 shares of the company’s stock valued at $91,771,000 after purchasing an additional 304,600 shares during the period. Finally, Millennium Management LLC purchased a new stake in TransMedics Group in the second quarter valued at $7,589,000. 99.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have commented on TMDX. Robert W. Baird began coverage on TransMedics Group in a research report on Wednesday, July 19th. They issued an “outperform” rating on the stock. TheStreet upgraded shares of TransMedics Group from a “d+” rating to a “c-” rating in a report on Friday, August 4th. Morgan Stanley cut their target price on TransMedics Group from $81.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Friday, October 13th. Oppenheimer raised their price target on TransMedics Group from $90.00 to $92.00 in a research report on Friday, August 4th. Finally, TD Cowen raised their price target on TransMedics Group from $95.00 to $110.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $81.00.
TransMedics Group Trading Down 0.1 %
NASDAQ:TMDX opened at $41.31 on Tuesday. The firm has a market cap of $1.35 billion, a PE ratio of -72.47 and a beta of 1.57. The stock has a fifty day moving average price of $56.52 and a 200 day moving average price of $71.15. TransMedics Group, Inc. has a 12-month low of $40.60 and a 12-month high of $99.63. The company has a current ratio of 20.70, a quick ratio of 19.74 and a debt-to-equity ratio of 3.48.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.12. The firm had revenue of $42.46 million during the quarter, compared to analyst estimates of $42.42 million. TransMedics Group had a negative return on equity of 9.98% and a negative net margin of 11.77%. TransMedics Group’s revenue was up 136.9% compared to the same quarter last year. During the same period last year, the business posted ($0.41) earnings per share. Sell-side analysts anticipate that TransMedics Group, Inc. will post -0.51 earnings per share for the current fiscal year.
Insider Activity at TransMedics Group
In related news, CEO Waleed H. Hassanein sold 7,500 shares of TransMedics Group stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $93.06, for a total value of $697,950.00. Following the completion of the transaction, the chief executive officer now directly owns 536,691 shares in the company, valued at $49,944,464.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 7,500 shares of TransMedics Group stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $93.06, for a total transaction of $697,950.00. Following the completion of the sale, the chief executive officer now directly owns 536,691 shares of the company’s stock, valued at approximately $49,944,464.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Gordon sold 5,000 shares of TransMedics Group stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.22, for a total value of $271,100.00. Following the sale, the chief financial officer now directly owns 18,789 shares of the company’s stock, valued at $1,018,739.58. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,708 shares of company stock worth $1,661,136. Company insiders own 6.70% of the company’s stock.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
- Five stocks we like better than TransMedics Group
- How to Invest in Fertilizer
- Las Vegas Sands Stock May No Longer Be a Gamble
- Overbought Stocks Explained: Should You Trade Them?
- MarketBeat ‘Stock of the Week’: Is Gen Digital Undervalued?
- The Most Important Warren Buffett Stock for Investors: His Own
- The Value Deepens for Medtech Stocks: Reversal Imminent
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
